

What the Second Opinion Experiences of Clinical Investigators Tell Us About the Current Management of Non-Hodgkin Lymphomas and Multiple Myeloma

Select Publications

Lonial

Argyriou AA et al. **Bortezomib-induced peripheral neuropathy in multiple myeloma: A comprehensive review of the literature.** *Blood* 2008;112(5):1593-9.

Attal M et al. **Maintenance treatment with lenalidomide after transplantation for MYELOMA: Final analysis of the IFM 2005-02.** *Proc ASH* 2010;Abstract 310.

Cavo M et al. **Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: A randomised phase 3 study.** *Lancet* 2010;376(9758):2075-85.

Cavo M et al. **Phase III study of double autotransplantation incorporating bortezomib-thalidomide-dexamethasone (VTD) or thalidomide-dexamethasone (TD) for multiple myeloma: Superior clinical outcomes with VTD compared to TD.** *Proc ASH* 2009;Abstract 351.

Cavo M et al. **Superior complete response rate and progression-free survival after autologous transplantation with up-front Velcade-thalidomide-dexamethasone compared with thalidomide-dexamethasone in newly diagnosed multiple myeloma.** *Proc ASH* 2008;Abstract 158.

Harousseau JL et al. **Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: Results of the IFM 2005-01 phase III trial.** *J Clin Oncol* 2010;28(30):4621-9.

Harousseau JL et al. **Bortezomib/dexamethasone versus VAD as induction prior to autologous stem cell transplantation (ASCT) in previously untreated multiple myeloma (MM): Updated data from IFM 2005/01 trial.** *Proc ASCO* 2008;Abstract 8505.

Kumar SK et al. **Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: Phase 1 results from the multicenter EVOLUTION study.** *Leukemia* 2010;24(7):1350-6.

Lokhorst HM et al. **A randomized phase 3 study on the effect of thalidomide combined with Adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma.** *Blood* 2010;115(6):1113-20.

Macro M et al. **Dexamethasone+thalidomide (Dex/Thal) compared to VAD as a pre-transplant treatment in newly diagnosed multiple myeloma (MM): A randomized trial.** *Proc ASH* 2006;Abstract 57.

McCarthy PL et al. **Phase III Intergroup study of lenalidomide versus placebo maintenance therapy following single autologous hematopoietic stem cell transplantation (AHSCT) for multiple myeloma: CALGB 100104.** *Proc ASH* 2010;Abstract 37.

Moreau P et al. **Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, non-inferiority study.** *Lancet Oncol* 2011;12(5):431-40.

Palumbo A et al. **Bortezomib, melphalan, prednisone and thalidomide followed by maintenance with bortezomib and thalidomide (VMPT-VT) for initial treatment of elderly multiple myeloma patients: Updated follow-up and impact of prognostic factors.** *Proc ASH* 2010;Abstract 620.

Palumbo A et al. **Thalidomide for treatment of multiple myeloma: 10 years later.** *Blood* 2008;111(8):3968-77.

Reeder CB et al. **A Phase II trial comparison of once versus twice weekly bortezomib in CYBORD chemotherapy for newly diagnosed myeloma: Identical high response rates and less toxicity.** *Proc ASH* 2009;Abstract 616.

Richardson PG et al. **Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.** *Blood* 2010;116(5):679-86.

Richardson PG et al. **High response rates and encouraging time-to-event data with lenalidomide, bortezomib, and dexamethasone in newly diagnosed multiple myeloma: Final results of a phase I/II study.** *Proc ASH* 2009;Abstract 1218.

Sonneveld P et al. **HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high-dose melphalan (HDM) and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma (MM).** *Proc ASH* 2010;Abstract 40.

S Smith

Federico M et al. **R-CVP versus R-CHOP versus R-FM as first-line therapy for advanced-stage follicular lymphoma: Final results of FOLLO5 trial from the Fondazione Italiana Linfomi (FIL).** *Proc ASCO* 2012;Abstract 8006.

Gregory SA et al. **Superior outcomes associated with earlier use: Experience with tositumomab and iodine I 131 tositumomab in 1,177 patients (pts) with low-grade, follicular, and transformed non-Hodgkin's lymphoma (NHL).** *Proc ASCO* 2005;Abstract 6561.

Morschhauser F et al. **Impact of induction chemotherapy regimen on response, safety and outcome in the PRIMA study.** *Proc ICML* 2011;Abstract 22.

Rummel MJ et al. **Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study.** *Proc ASCO* 2012;Abstract 3.

Rummel MJ et al. **Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: Final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany).** *Proc ASH* 2009;Abstract 405.

Salles G et al. **Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial.** *Lancet* 2011;377(9759):42-51.

Vidal L et al. **Rituximab maintenance for the treatment of patients with follicular lymphoma: An updated systematic review and meta-analysis of randomized trials.** *J Natl Cancer Inst* 2011;103(23):1799-806.

M Smith

Boehme V et al. **CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: An analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).** *Blood* 2009;113(17):3896-902.

Dreyling MH et al. **The t(11;14) disorders: How biology can drive therapy.** *ASCO Educational Book* 2006.

Feugier P et al. **Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: Influence of rituximab.** *Ann Oncol* 2004;15(1):129-33.

Geisler CH et al. **Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: A nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group.** *Blood* 2008;112(7):2687-93.

Gisselbrecht C et al. **Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.** *J Clin Oncol* 2010;28(27):4184-90.

Habermann TM et al. **Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.** *Br J Haematol* 2009;145(3):344-9.

Johnson NA et al. **Lymphomas with concurrent BCL2 and MYC translocations: The critical factors associated with survival.** *Blood* 2009;114(11):2273-9.

LaCasce AS et al. **Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: An analysis from the NCCN NHL Database.** *Blood* 2012;119(9):2093-9.

Savage KJ et al. **MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy.** *Blood* 2009;114(17):3533-7.

Sehn LH et al. **The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.** *Blood* 2007;109(5):1857-61.

Witzig TE et al. **An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.** *Ann Oncol* 2011;22(7):1622-7.

Palumbo

Fayers PM et al. **Thalidomide for previously untreated elderly patients with multiple myeloma: Meta-analysis of 1685 individual patient data from 6 randomized clinical trials.** *Blood* 2011;118(5):1239-47.

Gay F et al. **Updated results of a Phase II study using lenalidomide as post-transplant consolidation-maintenance therapy in elderly multiple myeloma patients.** *Haematologica* 2011;96(Suppl 2);Abstract 0905.

Lacy MQ et al. **Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma.** *Mayo Clin Proc* 2007;82(10):1179-84.

Ladetto M et al. **Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma.** *J Clin Oncol* 2010;28(12):2077-84.

Niesvizky R et al. **Phase 3b UPFRONT study: Safety and efficacy of weekly bortezomib maintenance therapy after bortezomib-based induction regimens in elderly, newly diagnosed multiple myeloma patients.** *Proc ASH* 2010;Abstract 619.

Niesvizky R et al. **BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.** *Blood* 2008;111(3):1101-9.

Paiva B et al. **The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients.** *Blood* 2009;114(20):4369-72.

Palumbo A et al. **Personalized therapy in multiple myeloma according to patient age and vulnerability: A report of the European Myeloma Network (EMN).** *Blood* 2011;118(17):4519-29.

Palumbo A et al. **Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: A randomized controlled trial.** *J Clin Oncol* 2010;28(34):5101-9.

Rajkumar SV et al. **Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: An open-label randomised controlled trial.** *Lancet Oncol* 2010;11(1):29-37.

San Miguel JF et al. **Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.** *N Engl J Med* 2008;359(9):906-17.

Horwitz

Coiffier B et al. **Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.** *J Clin Oncol* 2012;30(6):631-6.

D'Amore F et al. **High-dose chemotherapy and autologous stem cell transplantation in previously untreated peripheral T-cell lymphoma — Final analysis of a large prospective multicenter study (NLG-T-01).** *Proc ASH* 2011;Abstract 331.

Goldberg JD et al. **Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplant.** *Leuk Lymphoma* 2012;53(6):1124-9.

Horwitz SM et al. **Pralatrexate and gemcitabine in patients with relapsed or refractory lymphoproliferative malignancies: Phase 1 results.** *Proc ASH* 2009;Abstract 1674.

Horwitz S et al. **Second-line therapy with ICE followed by high dose therapy and autologous stem cell transplantation for relapsed/refractory peripheral T-cell lymphomas: Minimal benefit when analyzed by intent to treat.** *Proc ASH* 2005;Abstract 2679.

Le Gouill S et al. **Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: A study by the Société Française de Greffe de Moëlle et de Thérapie Cellulaire.** *J Clin Oncol* 2008;26(14):2264-71.

O'Connor OA et al. **Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: Results from the pivotal PROPEL study.** *J Clin Oncol* 2011;29(9):1182-9.

O'Connor OA et al. **Pralatrexate reverses the trend to progressive resistance to successive systemic treatment regimens in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL).** *Proc ASH* 2010;Abstract 4881.

Reimer P et al. **Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: Results of a prospective multicenter study.** *J Clin Oncol* 2009;27(1):106-13.

Savage KJ et al. **Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification.** *Ann Oncol* 2004;15(10):1467-75.

Shustov AR et al. **Complete remissions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma.** *Proc ASH* 2010;Abstract 961.

Leonard

Eichhorst BF et al. **First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia.** *Blood* 2009;114(16):3382-91.

Hallek M et al. **Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial.** *Lancet* 2010;376(9747):1164-74.

O'Brien S et al. **Inotuzumab ozogamycin (IO), a CD22 monoclonal antibody conjugated to calecheamicin, is active in refractory-relapse acute lymphocytic leukemia (R-R ALL).** *Proc ASH* 2011;Abstract 875.

Reynolds C et al. **A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia.** *Invest New Drugs* 2012;30(3):1232-40.

Sharman J et al. **A Phase 1 study of the selective phosphatidylinositol 3-kinase-delta (PI3K δ) inhibitor, CAL-101 (GS-1101), in combination with rituximab and/or bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia (CLL).** *Proc ASH* 2011;Abstract 1787.

Stevenson FK et al. **B-cell receptor signaling in chronic lymphocytic leukemia.** *Blood* 2011;118(16):4313-20.

Van Meerten T, Hagenbeek A. **CD20-targeted therapy: A breakthrough in the treatment of non-Hodgkin's lymphoma.** *Neth J Med* 2009;67(7):251-9.

Woyach JA et al. **Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: Long-term follow-up of CALGB study 9712.** *J Clin Oncol* 2011;29(10):1349-55.